Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2002 Sep;6(9):757-62.

Anti-tuberculosis drug resistance in community and prison patients, Orel Oblast, Russian Federation.

Author information

1
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. pps9@cdc.gov

Abstract

SETTING:

Orel Oblast, Russian Federation.

OBJECTIVES:

To determine baseline levels of anti-tuberculosis drug resistance in Orel Oblast.

DESIGN:

Drug susceptibility testing (DST) records from 1 July 1999 to 30 June 2000 for patients with sputum acid-fast bacilli smear-positive pulmonary tuberculosis were reviewed. Treatment and incarceration status were obtained from the tuberculosis register. Patients with 1 month or less of prior treatment were defined as new cases; those previously treated for more than 1 month were defined as retreatment cases.

RESULTS:

Of 246 smear-positive isolates, 212 (86%) had DST performed. Of these, 190 (90%) were from new and 22 (10%) from retreatment cases; 171 (81%) were from community and 41 (19%) were from prison patients. Any drug resistance was more common among prison than community patients (44% vs. 30%, P = 0.05). MDR-TB was found in 14 (6.6%) of 212 isolates, and was more prevalent in prison compared with community patients (12% vs. 5%, P = 0.05). Retreatment cases were more likely than new cases to have MDR-TB (prevalence ratio [PR] = 8.5, 95%CI = 3.3-22.3), although the PR was higher for prison than for community retreatment cases (10.0 vs. 5.8).

CONCLUSIONS:

New cases with MDR-TB were less prevalent in Orel Oblast compared with other survey sites in Russia. Any drug resistance and MDR-TB were associated with prior treatment, especially in the prison population. Continued monitoring of trends in drug resistance following DOTS implementation is needed.

PMID:
12234130
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center